沙利文授予药明康德2026年沙利文全球CRDMO年度公司奖

沙利文授予药明康德2026年沙利文全球CRDMO年度公司奖

Frost & Sullivan awards SULLIVAN China the '2026 Frost & Sullivan Global CRDMO Annual Company Award'.

发布时间:2026/10/29

沙利文授予药明康德2026年沙利文全球CRDMO年度公司奖

2026年

沙利文全球CRDMO年度公司奖


2026年10月20日,弗若斯特沙利文(Frost & Sullivan,以下简称“沙利文”)宣布,基于对CRDMO行业及全球医药研发市场的研究与评估,授予药明康德“2026年沙利文全球CRDMO年度公司奖”(2026 GLOBAL CRDMO COMPANY OF THE YEAR),以表彰其在赋能创新、卓越运营和客户价值方面的表现。这也是药明康德连续第十年获得沙利文颁发的最佳实践认可。


沙利文通过严格的基准评估流程,从战略有效性和战略执行力两大核心维度对企业进行评估。药明康德在这两方面均表现突出:其一体化CRDMO模式覆盖从早期发现到商业化生产的新药研发全流程,为客户提供贯穿药物研发全生命周期的服务。同时,药明康德的全球产能布局、稳健的运营表现,以及应对日益复杂的新分子类型的能力,充分体现了公司的差异化优势。


“药明康德凭借持续满足客户不断变化的创新需求在行业中脱颖而出,”沙利文医疗健康与生命科学业务副总裁Unmesh Lal表示,“作为全球生物医药创新领域值得信赖的合作伙伴,药明康德始终致力于帮助客户取得成功。”


“药明康德很荣幸再次获得沙利文的认可,这是对我们持续为客户创造价值的肯定。”药明康德董事长兼首席执行官李革博士表示,“作为行业坚定的赋能者,我们将继续聚焦CRDMO核心战略,助力全球客户加快创新疗法的研发进程,造福全球病患。”


创新是药明康德增长战略的核心。公司持续投资于新兴治疗模式和先进技术的开发与生产能力,包括寡核苷酸、多肽及相关偶联药物。这些投资有助于增强先导候选物的优化,并加速开发效率。


药明康德的卓越运营还体现在质量与监管合规方面。仅在2025年,公司就完成了741次监管检查和客户审计,无严重发现项(zero critical findings)。其“一个全球质量体系”支持各运营地点实现标准化治理和质量实践;一体化项目管理则使团队能够高效应对复杂的技术和监管挑战。


每年,沙利文将“全球年度公司奖”授予在战略制定与执行方面表现突出,并在市场地位、客户价值和竞争力方面实现可衡量提升的公司。该奖项旨在表彰那些在前瞻性创新、市场领先地位以及客户服务方面表现卓越的企业。


 关于药明康德 

公众号名称

药明康德(股票代码:603259.SH/2359.HK)是全球医药及生命科学行业值得信赖的合作伙伴和重要贡献者,致力于通过提供一体化、端到端的新药研发和生产服务,推动全球医药健康创新。公司在亚洲、欧洲、北美等地均设有运营基地,依托独特的“CRDMO”业务模式,不断降低研发门槛,助力客户提升研发效率,为患者带来突破性的治疗方案。目前,公司的赋能平台正承载着来自全球30多个国家的合作伙伴的研发创新项目,致力于将更多新药、好药带给全球病患,早日实现“让天下没有难做的药,难治的病”的愿景。


Frost & Sullivan awards WuXi AppTec with 2026 Global Company of the Year Recognition for CRDMO Leadership


SAN ANTONIO, Oct. 20, 2026 – Frost & Sullivan has awarded WuXi AppTec the 2026 Global Company of the Year Recognition in the CRDMO industry for its strong performance in enabling innovation, operational excellence, and customer impact.


Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. WuXi AppTec excelled in both: its integrated CRDMO model offers broad capabilities, global manufacturing capacity, and quality management across the full drug development cycle, supported by a network across Asia, Europe, and North America that maintains flexibility and operational resilience.


“WuXi AppTec distinguishes itself through its strong focus on evolving customer needs,” said Unmesh Lal, Vice President, Healthcare and Life Sciences at Frost & Sullivan. “Its commitment to customer success reinforces its position as a trusted partner to biopharmaceutical innovators worldwide.”


“We are honored that Frost & Sullivan has once again recognized what our teams deliver every day for customers,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec. “As a dedicated enabler of the pharmaceutical industry, we will remain committed to our CRDMO strategy, helping customers bring life-changing therapies to market faster and benefit patients around the world.”


Innovation is core to WuXi AppTec’s growth strategy. The company therefore continuously invests in its development and manufacturing capabilities for emerging therapeutic modalities and advanced technologies, including oligonucleotides, peptides and related conjugated medicines. These investments enhance lead candidate optimization and accelerate development efficiency.


WuXi AppTec’s operational excellence extends to quality and regulatory compliance. In 2025 alone, the company completed 741 regulatory inspections and customer audits with zero critical findings. Its One Global Quality System supports standardized governance and quality practices across operating locations, while integrated project management enables teams to address complex technical and regulatory challenges efficiently.


Each year, Frost & Sullivan presents the Global Company of the Year Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market position, customer value, and competitive strength. The recognition highlights forward-thinking organizations that are shaping their industries through innovation and growth excellence.



About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time.


推荐阅读

▸沙利文授予珍奥集团2026年沙利文全球5'-核苷酸技术创新领导奖

▸沙利文授予极巡科技2026年沙利文全球智能电动三轮车行业技术创新领导奖

▸沙利文授予杰华生物2026年沙利文全球大分子新药技术创新领导奖

▸沙利文授予凌科药业2026年沙利文全球自免及炎症小分子新药年度公司奖

▸沙利文授予青民数科2026年沙利文中国AI保险技术创新领导奖

▸沙利文授予未岚大陆 2026年沙利文中国无边界割草机器人年度公司奖

▸沙利文授予广州派真生物2026年沙利文全球基因疗法CRDMO技术创新领导奖

▸沙利文授予普洛药业2026年沙利文全球CDMO年度公司奖

▸沙利文授予酶好生活集团2026年沙利文全球酶基产品技术创新领导奖

▸沙利文授予薇姿2026年沙利文全球及中国二硫化硒洗发水市场领导奖

▸沙利文授予新石器2026年沙利文全球无人车行业年度公司奖

▸沙利文授予成都施贝康2026年沙利文全球心脑血管及呼吸新药研发年度公司奖

* 以上内容系沙利文研究团队基于市场研究得出,系团队研究成果的公示,研究所使用的部分信息来源于公开资料。如您对本次研究的结果有疑义,欢迎发送邮件至: 咨询。


获取报告

沙利文授予药明康德2026年沙利文全球CRDMO年度公司奖

×
请选择职位类别
请选择
×
联系我们
联系我们
电话

业务咨询热线

(021) 54075836

微信
扫码立即添加官方客服企业微信号,为您在线答疑。

扫码立即添加官方客服企业微信号,为您在线答疑。

二维码

扫码关注官方微信公众号

返回顶部
返回顶部

联系我们

×
请选择职位类别
请选择
×
沙利文授予药明康德2026年沙利文全球CRDMO年度公司奖